Celltrion’s Canadian subsidiary has launched its Yuflyma (adalimumab) 100mg/ml biosimilar version of AbbVie’s higher-strength Humira following a landmark first approval several months ago.
A positive letter of intent has been received by Celltrion from the pan-Canadian Pharmaceutical Alliance, which groups federal and provincial
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?